Shots:

• Angle and AstraZeneca entered into a supply agreement to develop and validate a methodology using ANGLE's existing Parsortix-based DNA damage response (DDR) assay to detect micronuclei in CTCs as DDR measure
• Assay development will occur in Guildford, UK, by the ANGLE's laboratory, and follows development and launch of two highly specific and sensitive DDR assays in 2023
• The time period for the development phase is 6 mos. AstraZeneca will pay £150,000 ($186.53M) to Angle

Ref: Angle | Image: Angle

Related News:- ANGLE Signs a Contract with Eisai for Liquid Biopsy Diagnostic Solution

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com